Skip to main content

ForgingBridges | NULIBRY Access and Support program is committed to providing affordability options for NULIBRY

ForgingBridges | NULIBRY offers financial assistance options for your patients and their parents or caregivers

Benefits Verification

ForgingBridges | NULIBRY will automatically conduct an insurance benefits verification for all NULIBRY families.

  • Determine insurance status
  • Support insurance denials or delays
  • Provide a sample appeals letter (if needed)
  • Communicate copay responsibility to the parent/caregiver

ForgingBridges | NULIBRY QuickStart Program

For eligible patients whose insurance coverage determination has been delayed by 5 or more days, ForgingBridges | NULIBRY provides NULIBRY at no cost.

ForgingBridges | NULIBRY Copay Assistance Program

Provides eligible commercially insured patients assistance with copay and coinsurance costs.
  • Pay as little as $0 for their prescription
  • The maximum benefit provided to any one patient via Copay Assistance is $100,000 per year

ForgingBridges | NULIBRY Patient Assistance Program (PAP)

ForgingBridges | NULIBRY provides support for patients who are uninsured or underinsured and meet certain financial qualifications.

  • Patients may qualify for free NULIBRY medication
  • A medical-grade freezer may also be provided for NULIBRY storage if not covered by insurance

Help your patients access the ForgingBridges | NULIBRY PAP

Download Form
forging bridges access support program logo

ForgingBridges | NULIBRY
Access and Support

For questions or additional info, give us a call. Our support team is ready to help.

Call 1-888-55BRIDGE
(1-888-552-7434)

Monday-Friday, 8 am-8 pm ET

The support you need starts here.

Forms & Other Resources >

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION

NULIBRY is indicated to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Potential for Photosensitivity

NULIBRY can make the patient oversensitive to sunlight. NULIBRY-treated patients or their caregivers are advised to avoid or minimize patient exposure to sunlight and artificial UV light and adopt precautionary measures when exposed to the sun, including wearing protective clothing and sunglasses, and use broad-spectrum sunscreen with high SPF in patients 6 months of age and older. If photosensitivity occurs, caregivers/patients are advised to seek medical attention immediately and consider a dermatological evaluation.

ADVERSE REACTIONS

The most common adverse reactions in NULIBRY-treated patients were infusion catheter–related complications (89%), pyrexia (fever) (78%), viral infection (56%), pneumonia (44%), otitis media (ear infection) (44%), vomiting (44%), and cough/sneezing (44%). Adverse reactions for rcPMP-treated patients were similar to the NULIBRY-treated patients.

PATIENT COUNSELING INFORMATION

Please read the FDA-approved NULIBRY Prescribing Information and Instructions for Use and follow the instructions on how to prepare and administer NULIBRY.

NULIBRY has a potential for photosensitivity; see Warnings and Precautions. Seek medical attention immediately if the patient develops a rash or if they notice symptoms of photosensitivity reactions (redness, burning sensation of the skin, blisters).

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see full Prescribing Information for NULIBRY.